×
About 4,443 results

ALLMedicine™ Endometrial Carcinoma Center

Research & Reviews  1,526 results

Clinicopathologic association and prognostic impact of microcystic, elongated and fragm...
https://doi.org/10.1111/jog.15335
The Journal of Obstetrics and Gynaecology Research; Qi X, Zhu L et. al.

Jul 1st, 2022 - As a special invasive pattern seen in low-grade endometrial carcinoma, microcystic, elongated and fragmented (MELF) pattern is related to lymph node metastasis. Tumor budding (TB) is another histological marker in many cancers associated with tumo...

Aberrant TRPC1 expression reflects stromal cervical invasion, lymphovascular invasion, ...
https://doi.org/10.1002/jcla.24560
Journal of Clinical Laboratory Analysis; Wang Y, Zhang C

Jun 28th, 2022 - Transient receptor potential channel 1 (TRPC1) promotes tumor growth and metastasis in endometrial carcinoma (EC) cell lines, whereas its clinical role in EC management remains unclear. Therefore, this study aimed to investigate the association of...

MicroRNA 182, 183, 200a, and 200b exhibit strong correlations but no involvement in PTE...
https://doi.org/10.1016/j.prp.2022.153986
Pathology, Research and Practice; Nishijima Y, Inoue N et. al.

Jun 25th, 2022 - In this study, we focused on five microRNAs (miRNAs) that have been reported to regulate phosphatase and tensin homolog deleted on chromosome 10 (PTEN) gene expression, namely miR-182, miR-183, miR-200a, miR-200b, and miR-205, and examined their r...

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02501096

Jun 24th, 2022 - This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg)...

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
https://clinicaltrials.gov/ct2/show/NCT05173987

Jun 24th, 2022 - The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carci...

see more →

Guidelines  9 results

Flowchart for the ESGO/ESTRO/ESP 2020 endometrial carcinoma guidelines.
https://doi.org/10.1136/ijgc-2021-002859
International Journal of Gynecological Cancer : Official ... Al-Booz H

Jul 25th, 2021 - Flowchart for the ESGO/ESTRO/ESP 2020 endometrial carcinoma guidelines.|2021|Al-Booz H,|epidemiology,

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
https://doi.org/10.1136/ijgc-2020-002230
International Journal of Gynecological Cancer : Official ... Concin N, Matias-Guiu X et. al.

Jan 6th, 2021 - A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since ...

ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Endometrial Cancer.
https://doi.org/10.1016/j.jacr.2020.09.001
Journal of the American College of Radiology : JACR; , Reinhold C et. al.

Nov 7th, 2020 - To date, there is little consensus on the role of pelvic imaging in assessing local disease extent during initial staging in patients with endometrial carcinoma, with practices differing widely across centers. However, when pretreatment assessment...

ACR Appropriateness Criteria® Management of Recurrent Endometrial Cancer.
https://doi.org/10.1097/COC.0000000000000318
American Journal of Clinical Oncology; Elshaikh MA, Vance S et. al.

Jul 12th, 2016 - In women with endometrial carcinoma (EC), tumor recurrences tend to occur in the 2- to 3-year period following surgical staging. Management of disease recurrence in EC poses significant challenges. These patients represent a heterogenous group whe...

ACR appropriateness Criteria® advanced stage endometrial cancer.
https://doi.org/10.1097/COC.0000000000000098
American Journal of Clinical Oncology; Elshaikh MA, Yashar CM et. al.

Jul 1st, 2014 - Patients with advanced stage endometrial carcinoma constitute a heterogeneous group of patients with different stages, tumor histologic types, and involved sites. Hysterectomy, bilateral salpingo-ophorectomy, and surgical staging are the cornersto...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  146 results

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02501096

Jun 24th, 2022 - This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg)...

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
https://clinicaltrials.gov/ct2/show/NCT05173987

Jun 24th, 2022 - The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carci...

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04205630

Jun 22nd, 2022 - This is an open-label, single-arm study in patients with HER2-expressing recurrent, advanced or metastatic endometrial carcinoma. HER2-expression is defined as a 1+, 2+ or 3+ score on immunohistochemistry (IHC) or positive by in situ hybridization...

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT05112601

Jun 21st, 2022 - PRIMARY OBJECTIVE: I. To assess efficacy in terms of progression-free survival (PFS) for immunotherapy with dual immune checkpoint blockade (nivolumab/ipilimumab) versus (vs.) monotherapy (nivolumab) in patients with recurrent mismatch repair (MMR...

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
https://clinicaltrials.gov/ct2/show/NCT03300557

Jun 21st, 2022 - PRIMARY OBJECTIVE: I. To determine if there is a decrease in proliferation index, measured by Ki-67 expression, in complex atypical hyperplasia (CAH)/endometrial intraepithelial neoplasia (EIN) or low grade (grade 1 and grade 2) endometrial cancer...

see more →

News  84 results

Two Distinct Subtypes of PCOS Identified in Adolescents
https://www.medscape.com/viewarticle/975815

Jun 17th, 2022 - Polycystic ovary syndrome (PCOS) in adolescents appears to present as two distinct subtypes based on the presence or absence of obesity, new data show. The findings support the "metabolic" and "reproductive" subtypes previously identified in adult...

BI 836880/Ezabenlimab Combo Had Limited Antitumor Activity, But Manageable Safety in Advanced MSS CRC
https://www.onclive.com/view/bi-836880-ezabenlimab-combo-had-limited-antitumor-activity-but-manageable-safety-in-advanced-mss-crc

May 2nd, 2022 - The VEGF/Ang2–targeting bispecific nanobody BI 836880, in combination with ezabenlimab (BI 754091), produced antitumor activity found to be comparable to that of available third-line therapy options in patients with advanced microsatellite stable ...

Trastuzumab in Endometrial Carcinoma Therapy
https://www.onclive.com/view/trastuzumab-in-endometrial-carcinoma-therapy

Mar 24th, 2022 - Krishnansu Tewari, MD: When do you integrate trastuzumab for that patient? Bradley Monk, MD, FACOG, FACS: That’s a good question. The patient was HER2 negative. David O’Malley, MD: As we look at this, without data, yes, I expect that arm is goin...

I/O + Chemotherapy Treatments for Endometrial Carcinoma
https://www.onclive.com/view/i-o-chemotherapy-treatments-for-endometrial-carcinoma

Mar 18th, 2022 - Bradley Monk, MD, FACOG, FACS: This patient recurs; she’s chemotherapy-naïve, so she’s in the second bucket of stage IV recurrent, and chemotherapy is the standard. We’re doing some studies in this setting, adding a checkpoint inhibitor to the che...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

see more →